Author Archives: admin


Stem Cell Clinic > Articles by: admin

CytoDyn’s Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on…

By Stem Cell Medical Center

VANCOUVER, Washington, Sept. 22, 2020 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Phase 2 study of leronlimab for mild-to-moderate COVID-19 patients has been selected for an oral presentation at the upcoming Special isirv-Antiviral Group Conference on Therapeutics for COVID-19. The Conference is sponsored by the International Society for Influenza and other Respiratory Virus Diseases, an independent and international scientific professional society promoting the prevention, detection, treatment, and control of influenza and other respiratory virus disease.

Details of the presentation are as follows:

Abstract Title:A Phase 2 Study of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19). Abstract Confirmation Number:AAVGV0010 Presenter:Harish Seethamraju, M.D., Medical Director, Advanced Lung Failure and Lung Transplant, Montefiore Medical Center, Bronx, New York. Presentation Date and Time:October 6-8, 2020 12.00-4.00pm GMT and will be available on demand.

Additional details can be found on the conference web sitehere

The acceptance of this oral abstract by this highly regarded scientific organization is very rewarding for all of the medical professionals who provided care and treatment to the COVID-19 patients during our Phase 2 trial. We also view this acceptance as a validation of leronlimab as a potential therapeutic for this disease and we look forward to the upcoming interim analysis from our Phase 3 trial for severe-to-critical COVID-19 patients, said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn.

About Coronavirus Disease 2019 CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate patients in the U.S. which produced statistically significant results for NEWS2. Enrollment continues in its Phase 3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals throughout the U.S.; an interim analysis on the first 195 patients will be announced by mid-October.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.Leronlimab has completed nine clinical trials in over 800 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells.CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.

CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. The FDA met telephonically with Company key personnel and its clinical research organization and provided written responses to the Companys questions concerning its recent Biologics License Application (BLA) for this HIV combination therapy in order to expedite the resubmission of its BLA filing for this indication.

CytoDyn has completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than six years.

CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companys cash position, (ii) the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv) the Companys ability to enter into partnership or licensing arrangements with third parties, (v) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companys ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companys clinical trials, (viii) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTS Investors: Michael Mulholland Office: 360.980.8524, ext. 102 mmulholland@cytodyn.com

The rest is here:
CytoDyn's Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on...

Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to…

By Stem Cell Medical Center

Details Category: Antibodies Published on Tuesday, 22 September 2020 10:41 Hits: 601

Adjuvant Opdivo doubled disease-free survival; is the first therapeutic option to show statistically significant and clinically meaningful disease-free survival benefit in these patients, regardless of tumor histology, following chemoradiation therapy and resection

Results from Phase 3 CheckMate -577 trial selected for presentation during a Presidential Symposium at the European Society for Medical Oncology Virtual Congress 2020

PRINCETON, NJ, USA I September 21, 2020 I Bristol Myers Squibb (NYSE: BMY) today announced first results from the Phase 3 CheckMate -577 trial in which adjuvant treatment with Opdivo (nivolumab) showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS), the trials primary endpoint, compared to placebo in patients with esophageal or gastroesophageal junction (GEJ) cancer following neoadjuvant chemoradiation therapy (CRT) and tumor resection. The current standard of care for patients with esophageal or GEJ cancer following neoadjuvant CRT and tumor resection is surveillance. These results signify the first time an adjuvant therapeutic option has significantly prolonged DFS for patients in this setting.

Median DFS was doubled in patients receiving Opdivo [22.4 months; (95% Confidence Interval [CI]: 16.6 to 34.0)] compared to those receiving placebo after surgery [11.0 months; (95% CI: 8.3 to 14.3)] (Hazard Ratio [HR] 0.69; 96.4% CI: 0.56 to 0.86; p=0.0003). The median duration of treatment for patients in the Opdivo arm was just over 10 months [10.1 months (<0.1 to 14.2)] versus nine months for patients in the placebo arm [9.0 months (<0.1 to 15)]. The safety profile of Opdivo in CheckMate -577 was consistent with previously reported studies of Opdivo monotherapy.

While about 25% to 30% of patients with esophageal or gastroesophageal junction cancer achieve a complete response following chemoradiation therapy and surgery, the remaining 70% to 75% do not, and there is currently no adjuvant treatment option available for these patients with the potential to improve their outcomes, said Ronan J. Kelly M.D., MBA, Director, Charles A. Sammons Cancer Center at Baylor University Medical Center. Adjuvant treatment with nivolumab in the CheckMate -577 trial doubled patients time without disease recurrence, representing the first adjuvant treatment advancement for these patients with esophageal or gastroesophageal junction cancer.

Opdivo was well tolerated with an acceptable safety profile relative to placebo. The majority of patients in the Opdivo arm (89%) were able to receive a relative dose intensity of 90%. The incidence of any treatment-related adverse events (TRAEs), including any grade and Grade 3-4, was 71% and 13% among patients treated with Opdivo compared to 46% and 6% among patients receiving placebo. Serious TRAEs of any grade and Grade 3-4 occurred in less than 10% of patients treated with Opdivo (any grade in 8%, Grade 3-4 in 5%) compared to 3% and 1% of patients receiving placebo, with a low rate of any grade treatment-related discontinuations in both arms (9% for Opdivo vs. 3% in placebo).

These results make esophageal and gastroesophageal junction cancer the second cancer type following melanoma where Opdivo has demonstrated a benefit in the adjuvant setting, indicating the potential for Opdivo to become a new standard of care for these patients, said Ian M. Waxman, M.D., development lead, Gastrointestinal Cancers, Bristol Myers Squibb. This advancement showcases our commitment to evaluating our therapies in earlier stages of disease where we may be able to have a greater impact on preventing disease recurrence and improving patient outcomes. We look forward to discussing these encouraging results from CheckMate -577 with global health authorities in the coming months.

These data (Presentation #LBA9) will be featured in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on September 21 from 19:31-19:43 CEST.

About CheckMate -577

CheckMate -577 is a Phase 3 randomized, multi-center, double-blind study evaluating Opdivo as an adjuvant therapy in patients with resected esophageal or GEJ cancer who have received neoadjuvant CRT therapy and have not achieved a pathological complete response. The primary endpoint of the trial is DFS and the secondary endpoint is overall survival (OS). Following neoadjuvant CRT therapy and complete tumor surgical resection (also known as trimodality therapy), a total of 794 patients were randomized to receive placebo (n=262) or Opdivo (n=532) 240 mg by intravenous infusion every two weeks for 16 weeks followed by Opdivo 480 mg every four weeks until disease recurrence, unacceptable toxicity or withdrawal of consent, with a maximum of one year total treatment duration.

About Esophageal Cancer

Esophageal cancer is the seventh most common cancer and the sixth leading cause of death from cancer worldwide, with approximately 572,000 new cases and over 508,000 deaths in 2018. The two most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma, which account for approximately 85% and 15% of all esophageal cancers, respectively, though esophageal tumor histology can vary by region with the highest rate of esophageal adenocarcinoma occurring in North America (65%). The majority of cases are diagnosed in the advanced setting and impact a patients daily life, including their ability to eat and drink.

About Gastric Cancer

Gastric cancer, also known as stomach cancer, is the fifth most common cancer and the third leading cause of cancer death worldwide, with over 1,000,000 new cases and approximately 783,000 deaths in 2018. There are several cancers that can be classified as gastric cancer, including certain types of cancers that form in the GEJ, the area of the digestive tract where the esophagus and stomach connect. While GEJ cancer has a lower prevalence than gastric cancer, it continues to rise.

Bristol Myers Squibb: Advancing Cancer Research

At Bristol Myers Squibb, patients are at the center of everything we do. The goal of our cancer research is to increase patients quality of life, long-term survival and make cure a possibility. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients.

Building upon our transformative work and legacy in hematology and Immuno-Oncology that has changed survival expectations for many cancers, our researchers are advancing a deep and diverse pipeline across multiple modalities. In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early- to mid-stage development. Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Combining these approaches is key to delivering potential new options for the treatment of cancer and addressing the growing issue of resistance to immunotherapy. We source innovation internally, and in collaboration with academia, government, advocacy groups and biotechnology companies, to help make the promise of transformational medicines a reality for patients.

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the bodys own immune system to help restore anti-tumor immune response. By harnessing the bodys own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Opdivos leading global development program is based on Bristol Myers Squibbs scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. In October 2015, the Companys Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.

INDICATIONS

OPDIVO (nivolumab), as a single agent, is indicated for the treatment of patients with unresectable or metastatic melanoma.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

OPDIVO (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

OPDIVO (nivolumab) is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).

OPDIVO (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO (nivolumab) is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

OPDIVO (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO (nivolumab), as a single agent, is indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO (nivolumab) is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO (nivolumab) is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

CheckMate Trials and Patient Populations

Checkmate 037previously treated metastatic melanoma; Checkmate 066previously untreated metastatic melanoma; Checkmate 067previously untreated metastatic melanoma, as a single agent or in combination with YERVOY; Checkmate 227previously untreated metastatic non-small cell lung cancer, in combination with YERVOY; Checkmate 9LApreviously untreated recurrent or metastatic non-small cell lung cancer in combination with YERVOY and 2 cycles of platinum-doublet chemotherapy by histology; Checkmate 017second-line treatment of metastatic squamous non-small cell lung cancer; Checkmate 057second-line treatment of metastatic non-squamous non-small cell lung cancer; Checkmate 032small cell lung cancer; Checkmate 025previously treated renal cell carcinoma; Checkmate 214previously untreated renal cell carcinoma, in combination with YERVOY; Checkmate 205/039classical Hodgkin lymphoma; Checkmate 141recurrent or metastatic squamous cell carcinoma of the head and neck; Checkmate 275urothelial carcinoma; Checkmate 142MSI-H or dMMR metastatic colorectal cancer, as a single agent or in combination with YERVOY; Checkmate 040hepatocellular carcinoma, as a single agent or in combination with YERVOY; Checkmate 238adjuvant treatment of melanoma; Attraction-3esophageal squamous cell carcinoma

About the Bristol Myers Squibb and Ono Pharmaceutical Collaboration

In 2011, through a collaboration agreement with Ono Pharmaceutical Co., Bristol Myers Squibb expanded its territorial rights to develop and commercialize Opdivo globally, except in Japan, South Korea and Taiwan, where Ono had retained all rights to the compound at the time. On July 23, 2014, Ono and Bristol Myers Squibb further expanded the companies strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens for patients with cancer in Japan, South Korea and Taiwan.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

SOURCE: Bristol-Myers Squibb

Go here to see the original:
Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to...

Coming of Age: New Research Efforts are Improving Treatment of Childhood Blood Cancers – Curetoday.com

By Stem Cell Doctors

Over Mothers Day weekend 2011, Kimberly Schuetz took her 2-year-old son on a road trip from their hometown of Fall River, Wisconsin, to visit family in Illinois. Leading up to the journey, Austin had been his normal, energetic self.

He was eating like a horse and being very active, very playful. No sicknesses, fevers, or anything like that, Schuetz says.

On Saturday, Schuetzs father-in-law noticed something alarming while tickling his grandson. One of Austins lymph nodes on his neck had swollen to the size of a golf ball. As an oncology nurse, Schuetz immediately had a sick feeling in her stomach. Her mind went straight to thoughts of cancer.

While her gut reaction told her to take Austin to the emergency department, Schuetz decided to wait until Monday to visit his pediatrician back home. After all, her son was acting fine.

A week later, after visits to two pediatricians, the emergency department at their local hospital and pediatric hematologists at a childrens hospital, a bone marrow biopsy confirmed that Austin had acute lymphoblastic leukemia (ALL). A cancer of the blood and bone marrow, ALL is the most common type of cancer that occurs in children.

I literally felt like I was living somebody elses life, like I was watching a movie. I remember sitting there and listening to the doctor, but I also felt like I was floating above myself, Schuetz says. I was numb and couldnt cry. Your brain just goes into this state of shock.

Omar Durani, a family physician in Dallas, Texas, went through similar feelings when his 9-month-old daughter Kenza received an acute myeloid leukemia (AML) diagnosis. In 2016, her swollen lymph nodes signaled to Durani and his wife that something wasnt right.

As a physician and dad, its kind of difficult to figure out what hat to wear when, and how much to worry about things like that, he says. When the swelling worsened, we started advocating for blood work, but all the doctors we visited only kept giving her antibiotics.

Finally, an emergency department physician who Durani knew personally listened to their concerns and performed blood testing. The results came back with white cell counts through the roof, confirming the familys worst fears: Kenza had cancer.

Both ALL and AML are treated initially with chemotherapy, and for the vast majority of children, it works. More than 95% of children with ALL and about 85% to 90% of those with AML enter remission after the first phase of chemotherapy. However, remission does not necessarily mean a cure.

Austin relapsed in October 2012 after two phases of chemotherapy, and despite receiving a bone marrow transplant, his ALL came back a third time in May 2013. About 10% to 20% of children with ALL have a disease that relapses or is resistant to treatment. At that point, with no treatment options left, Austins parents were told he had three to six months to live.

We live 45 minutes away from the hospital, and our doctor ended up driving to our house, not to offer any solutions, because we didnt have a plan, but just to sit and cry with us, because she was so heartbroken and, in such disbelief, Schuetz says.

Some cancer in children does not respond to chemotherapy. After three rounds of chemotherapy, doctors told Durani that his daughters only hope would be a bone marrow transplant. But as a child of Asian descent and mixed ethnic background, Kenza had a less than 2% chance of finding a bone marrow donor match.

While research in adult blood cancers has led to an explosion of new targeted therapies and immunotherapies, such progress has been slower for younger patients. This can leave children such as Austin and Kenza without a path forward. Even for patients who do achieve long-term survival, the lingering toxicity of chemotherapy can lower their quality of life as adults.

Only four cancer treatments have been approved for first use in children in the last 40 years, compared with hundreds approved for treating adults during this same time frame, said Dr. Gwen Nichols, chief medical officer of the Leukemia & Lymphoma Society (LLS).

Out of all the federal funding that goes into cancer research, only 4% goes toward pediatric cancer research, said Dr. Deepa Bhojwani, director of the Leukemia and Lymphoma Program

at Childrens Hospital Los Angeles in California. That being said, I would say within the last five to 10 years, there has been a lot more progress in terms of targeted treatment and immunotherapy than there was in the past.

But the tide may be turning for this young, vulnerable population with new research initiatives dedicated to applying precision medicine to pediatric blood cancers. Much of todays research in pediatric blood cancers aims to find tailored alternatives to chemotherapy that could prove just as or more effective with fewer harmful side effects.

Cancer is still the leading cause of death from disease among children and adolescents in the United States. From 2012 to 2016, leukemia and lymphoma accounted for 38.7% of all cancer types for patients under age 20. Approximately 40% of children with AML and 20% of those with ALL experience a relapse of their disease. Non-Hodgkin lymphoma, the most common type of lymphoma in children under age 14, that is resistant to first-line therapy has a very poor prognosis.

Before joining LLS, Nichols worked for a pharmaceutical company. She says that getting pediatric drugs tested and approved may be difficult because they typically do not bring in as much revenue as adult therapies.

As a result, upon arriving at LLS she was determined to figure out a faster, more efficient way to bring new agents and therapies to children with blood cancers.

In 2016, LLS launched the Beat AML Master Trial for adults with AML. It represented a paradigm shift in the format of clinical trials by testing several different targeted therapies in individual study arms instead of only one drug or combination of drugs at a time. Patients had a genomic screening to determine whether they had one of the genetic mutations that would make them eligible for one of the study arms to test a particular targeted therapy.

Its about 50% less expensive to do a master trial than it is to do one drug at a time. So, we needed to do something similar in pediatrics to make it more cost-efficient. But even more than that, if you want to get targeted therapies to kids, you have to have the right kids to test the drug, Nichols said. If youre doing one drug at a time, you have to screen thousands of kids to find the five that fit your drug, which costs time and money.

In 2019, LLS announced a collaboration with the National Cancer Institute and the Childrens Oncology Group called LLS PedAL (Pediatric Acute Leukemia), a global precision medicine master clinical trial in the same vein as the Beat AML trial. Children with relapsed acute leukemia will undergo genomic screening to match the specific abnormalities driving their cancer with one of several targeted therapies.

As part of The LLS Childrens Initiative: Cures and Care for Children, a $100 million, multiyear effort to take on pediatric blood cancers, LLS PedAL will test multiple agents simultaneously at up to 200 sites worldwide. Trials will follow the same format so that data from multiple institutions can be shared and consolidated.

Nichols and her colleagues hoped to begin the trial this year, but with the coronavirus disease 2019 pandemic, LLS PedALs start date has been pushed back to early 2021.

Another inspiring research project is the Pediatric Cancer Genome Project (PCGP), a joint initiative from St. Jude Childrens Research Hospital and Washington University School of Medicine. Since 2010, the two insti- tutions have pioneered efforts to define the genomic landscape of pediatric cancer by sequencing the genomes of normal and cancer cells from 800 patients.

That work really filled in much of the landscape of mutations that drive ALL, AML and many of the other kinds of pediatric cancer, says Dr. James R. Downing, president and CEO of St. Jude, who was instrumental in launching the PCGP. In particular, important fundamental discoveries came out for ALL in terms of new understandings related to the identification of new genetic subtypes, amplifications, fusions and chromosomal translocations of the disease.

For instance, the PCGP pinpointed genes linked to an ALL subtype with a poor prognosis known as Philadelphia chromosome-like ALL (Ph-like ALL). In 2009, St. Jude scientists were among the first to describe Ph-like ALL in children. Five years later, next-generation sequencing revealed the genetic alterations that give rise to Ph-like ALL, which could be targeted with drugs widely used to treat other types of leukemia more common in adults.

A 2017 study from the PCGP identified potential targets for immunotherapies in pediatric cancers, finding that 88% of leukemias have at least one that could be exploited. A 2018 pan-cancer analysis that examined commonalities and differences among various cancer types, including ALL and AML, suggest that half of the cancers studied may have a targeted treatment available or under development.

The second phase of the genome project is moving all that technology into frontline diagnostics, Downing says. So now were getting the whole genome, whole exome and RNA sequencing of every patient, and we gain insight that can be funneled into a protocol that allows them to be treated.

St. Judes frontline ALL protocol includes an unparalleled level of genomic sequencing on the patient, on both cancer and normal cells, which allows physicians to make personalized therapeutic decisions. Downing hopes that collecting such a wealth of data will help usher in new therapies and lead to a further improvement in outcomes.

So the momentum is there, the studies are ongoing, and hopefully five years from now, we will have a huge variety of therapies to offer our kids instead of just one, Bhojwani says.

Bhojwani participates in the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium, which has its headquarters at Childrens Hospital Los Angeles. TACL brings together childrens hospitals and universities to accelerate the progress of new therapies for pediatric leukemia and lymphoma. The consortium includes 31 institutions in the United States and Australia that collaborate on clinical trials of new drugs and novel therapy combinations in the hopes of expanding the number of treatments available.

Both Kenza and Austin were saved by an experimental treatment called chimeric antigen receptor (CAR)-T cell therapy administered in a clinical trial. It involves engineering the bodys T cells, a type of white blood cell, to produce receptors on their surface called chimeric antigen receptors (CARs). The engineered cells are infused back into the patient, where they can recognize and kill cancer cells.

The Duranis couldnt find a bone marrow donor match for Kenza, despite having more than 60 donor drives inspired by her diagnosis that registered more than 5,000 new potential bone marrow donors around the country. At that point, they decided to move forward with CAR-T cell therapy coupled with a haploidentical, or partially matched, stem cell transplant in August 2016.

It was a no-brainer for us since there were no other therapies available besides a standard bone marrow transplant, Durani says. Now Kenzas been in remission for four years, and shes doing fantastic. Shes a thriving, spunky 5-year-old.

After his third relapse, Austins parents enrolled him in a clinical trial to receive CAR-T cell therapy as a last- ditch effort to save their son. He received the treatment at the beginning of October, and on Halloween which also happens to be his mothers birthday they received the good news that his biopsy showed no traces of cancer.

I immediately started screaming and crying. I was just elated. It was the best birthday present that I could ever, ever have. Nothing will ever top that, Schuetz says.

Today, Austin is a typical 12-year-old boy who enjoys video games, swimming with his friends and complaining about household chores. He and Kenza are living proof that innovations such as CAR-T cell therapy give children who have run out of options another chance at life.

Read more here:
Coming of Age: New Research Efforts are Improving Treatment of Childhood Blood Cancers - Curetoday.com

Guide to Voting on Propositions and the City of San Bernardino’s Measure S – Black Voice News

By Stem Cell Doctors

Local Measure

San Bernardino Measure S

NO on Measure S in San Bernardino: It would raise taxes so the mayor can pay for sexual harassment lawsuits and give tax dollars to employees who work for the city but do not live in the city. Currently only 10% of the employees working for the city are Black and only 5% work in the police department. Only 8% of the sworn police officers live in the city and the city has never hired a Black as chief of police in 115 years. Blacks make up 13.8% of the city population and pay taxes.

Propositions

Proposition 14

NO on Prop 14: Taxpayers will be on the hook for $5.5 billion in bonds aimed at reviving the California Institute for Regenerative Medicine (CIRM), a program created in 2004 to boost stem cell research.

Proposition 15

NO on Prop 15: It would leave Californias Prop13 tax rules unchanged, which is a benefit to older Black homeowners. Small businesses will see their rents increase. This will hurt in the long run and the County Assessors offices up and down the state said it is unworkable.

Proposition 16

YES on Prop 16: It would be a giant step to help undo the results of long-standing institutionalized race and gender discrimination that have been key to economic and social inequality. This would put California back in step with Federal Laws governing Equal Opportunity in Employment, access to educational institutions of higher learning and provide fair access to government contracts for women and minority owned businesses.

Proposition 17

YES on Prop 17: It would make it legal for people who have paid their debt to society to vote while on parole for a felony conviction.

Proposition 18

YES on Prop 18: It would make it legal for people who will turn 18 in time for the general election to vote, even while still 17, at the time of that years primary.

Proposition 19

NO on Prop 19: Currently, a parent or grandparent can bestow their low tax rate while passing on a rental home or vacation property. This feature would be eliminated under Prop 19.

Proposition 20

NO on Prop 20: This initiative is being bankrolled by the states prison guards union and they are trying to keep the prisons full to protect their jobs. Plus, it will be unjust to Blacks and Hispanic people by adding stiffer penalties for those who violate the terms of their parole three times and require DNA samples be taken from people convicted of misdemeanors.

Proposition 21

NO on Prop 21: Some say it could make a dent in homelessness, a problem that is a crisis in our community. However, rent control does not work as some have learned and a rent board would be in charge of the owners property.

Proposition 22

YES on Prop 22: This initiative is about independent thinking people who use their own cars and cell phones to work when they want to, depending on their personal life situation. A yes vote will provide new benefits such as healthcare and a minimum wage. Plus, we have a lot of Black people who love working for themselves.

Proposition 23

NO on Prop 23: This legislation would require at least one physician to be on site at an operating dialysis clinic adding more expense to those who need the service. There are not enough doctors to do this work and the cost would eliminate many clinics in Black and Brown communities.

Proposition 24

NO on Prop 24: This measure would expand and add to Californias two-year-old law on consumer data privacy and create another layer to an already confusing system.

Proposition 25

NO on Prop 25: This is a risk assessment system that would replace cash bail and is biased because it uses a computer program that is inflexible to human special needs in this special time of need.

Hardy Brown Sr. is Publisher Emeritus of the Black Voice News.

Visit link:
Guide to Voting on Propositions and the City of San Bernardino's Measure S - Black Voice News

World Rose Day 2020: History and significance of the welfare of cancer patients – Hindustan Times

By Stem Cell Doctors

World Rose Day is annually celebrated on September 22 in dedication to the welfare of cancer patients. (Pixabay)

World Rose Day is annually celebrated on September 22 in dedication to the welfare of cancer patients. On this day, people around the world work towards bringing cheer and hope into the lives of all those people who have been affected by cancer. More importantly, it seeks to remind patients and their caregivers, that they are not alone in this battle against the deadly disease.

Cancer treatments are quite tasking on the body and mind of those who have been affected. With the changes their bodies encounter and the sheer mental trauma of being ravaged by this disease can wreak havoc with most people. According to Dr. Ganapathi Bhat, Consultant Medical Oncologist and Stem cell Transplant Physician at Jaslok Hospital & Research Centre, The financial costs associated with cancer are often overwhelming. Cancer affects a persons diet and eating habits in many ways. The illness can in itself cause weight loss, lack of appetite or other problems associated with eating. Cancer also often affects your self-image and self-esteem. Possible changes in physical appearance and depleted health can be frightening. Having cancer can undermine your mental and physical wellbeing. But by making even the simplest gestures of kindness, each and every one of us can bring some comfort to their lives. Even though that alone is not enough to cure them, it can certainly ease their suffering.

World Rose Day for the Welfare of Cancer Patients was first observed in honour of 12-year-old Melinda Rose from Canada, who was diagnosed with a rare form of blood cancer known as Askins Tumour. Even while the doctors had only given her weeks to live, she went on to live for 6 months and spent her time bringing joy and hope to all the diagnosed people around her. She reached out to all the cancer patients, sharing poems, letters and emails with them, to bring some cheer into their lives. Her kindness and optimism serve as a reminder to us all, that even in the most bleak of all situations, hope is what keeps us going.

By offering roses to cancer patients and their caregivers, people extend their concern and offer tenderness in the face of this harsh disease. Unfortunately, the medical and science fields are yet to come up with an absolute cure for cancer, despite their constant dedication to this cause, we can all contribute in our own way by being mindful of their suffering and ensuring that we care for them and contribute to their strength so that they may continue fighting.

Follow more stories on Facebook and Twitter

Here is the original post:
World Rose Day 2020: History and significance of the welfare of cancer patients - Hindustan Times

CARLTON FLETCHER: McConnell is the poster boy for sleazy, partisan politics – The Albany Herald

By Stem Cell Doctors

Oh ... How do you sleep at night?

Ive often complained that I dont understand politics or politicians, but the truth is, I dont really want to.

I dont know what it is that makes men and women who say they want to run for office to help make their country, state, county, city a better place and then find themselves sucked into the madness that is American politics. Its a vocation that takes pretty much decent human beings and turns them into lying, cheating, double-talking cretins who make used car salesmen (no offense) look like followers of Mother Teresa.

Ive found it amazing over the years that politicians the ones who settle in for the long haul, pulling their chairs up to the pork, PAC and lobbyist troughs and just digging in like the pigs and gluttons they become think the American people are so stupid they actually believe their double-talk and bull----. By the same token, however, why would they think otherwise? The American people, who get an up-close, first-hand view of their shenanigans, keep sending them back to Washington, Atlanta, and local government agencies with hardly a second thought.

What? My elected representatives at the highest level cashed in certain stocks and bought up others after they attended a meeting that gave them advance warning of the possible impact of the coronavirus pandemic? Well, thats just good business. What, the businessman we put in the highest office in the land filed 13 bankruptcies and cheated both the American taxpayer and businesses he owed out of millions of dollars? That just shows hes got down the art of the deal, baby.

Did you say the person who wants to be president has changed his mind on important issues depending on which way the wind is blowing on a particular day so many times that he doesnt even know where he stands on those issues? Thats called playing to your base. Everyone does it.

I think Ive made it clear over the years my disdain for Kentucky Sen. Mitch McConnell. From his opposing stem cell research because the extreme right of his party opposed doctors and scientists playing God ... until someone in his family benefited from the science, to proclaiming that the entire Republican party should focus all of its efforts on making sure Barack Obama did not get a second term in office ON THE NIGHT HE WAS ELECTED, McConnell is the poster boy for lousy, self-serving, partisan politics at its worst.

As majority leader of the Senate, McConnell has spent the last 12 years the eight years that Obama was president and the four that Donald Trump has held that office doing nothing but putting conservative judges in office. McConnell conceded that the Democratic-controlled House would not go along with his right-wing agenda, so he has had the Senate do nothing but vote on judges over the last decade-plus. Other than hold a time-wasting impeachment trial that a group of power-tripping and wrong-headed Democrats dreamed up in the House, McConnell has proved to be the epitome of all that is wrong in American politics.

But the turtle man has outdone himself in his hypocritical call to replace recently passed Supreme Court Justice Ruth Bader Ginsburg before her body was even cool following her death from cancer. Wasnt it McConnell, you might ask, who led the charge to keep an Obama Supreme Court nominee from taking a seat on the high court at the end of his tenure in the White House? Yes, but see, McConnell has an answer to such charges of blatant hypocrisy and just out-right lying. He says that when Obama, a Democrat, was in office, the Senate was controlled by Republicans, so there were obvious philosophical differences. Now, with a Republican in the White House and a Republican Senate, he says, its OK.

Meaning? More political blather and bull----.

McConnell has long since proved himself a shameful self-serving opportunist whose traitorous actions in a better time would have landed him in prison or out of the government on his duff. With his disregard for Ginsburgs service, he has also shown himself to be the only passably human ghoul that only the lowest of the low aspire to. The people of Kentucky must be proud ... as they send him back to the trough to misuse and misappropriate more of our hard-earned money.

Email Carlton Fletcher at carlton.fletcher@ albanyherald.com.

See the rest here:
CARLTON FLETCHER: McConnell is the poster boy for sleazy, partisan politics - The Albany Herald

Blood Cancer Awareness Month 2020 – Everyday Health

By Stem Cell Doctors

Professional conferences and meetings offer an opportunity for doctors, researchers, and pharmaceutical professionals to share the latest research and findings on blood cancer. Like some of the runs and walks, many conferences have been postponed or moved to a virtual setting as a result of the COVID-19 pandemic.

Upcoming conferences and meetings include:

The Leukemia & Lymphoma Society held its 2020 National Blood Cancer Conference virtually on September 12 from 11:30 a.m. to 2:45 p.m. EDT. The educational event will be open to caregivers, patients, survivors, and family members of those affected, and review treatment options, emerging therapies, and resources provided by LLS.

LSS will hold its virtual conferences on September 26 hosted by the organizations Georgia/South Carolina region and October 3, hosted by LSSs Metro New York region. Additionally, LLS will host more virtual conferences throughout October and November.

The ASH will hold it's virtual meeting December 5-8 and is the largest conference on blood-related illnesses in the world.

RELATED: New Study Sheds Light on Genetic Differences in Types of Lymphoma

See original here:
Blood Cancer Awareness Month 2020 - Everyday Health

Stem Cell Therapy Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 – The Daily Chronicle

By Embryonic Stem Cells

Allosource

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=33553

Additionally, the report is furnished by the advanced analytical data from SWOT analysis, Porters Five Forces Analysis, Feasibility Analysis, and Investment Return Analysis. The report also provides a detailed analysis of the mergers, consolidations, acquisitions, partnerships, and government deals. Along with this, an in-depth analysis of current and emerging trends, opportunities, threats, limitations, entry-level barriers, restraints and drivers, and estimated market growth throughout the forecast period are offered in the report.

Market Breakdown:

The market breakdown provides market segmentation data based on the availability of the data and information. The market is segmented on the basis of types and applications.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Request customization of the report @https://reportsglobe.com/need-customization/?rid=33553

The report provides additional analysis about the key geographical segments of the Stem Cell Therapy Market and provides analysis about their current and previous share. Current and emerging trends, challenges, opportunities, and other influencing factors are presented in the report.

Regional analysis includes an in-depth study of the key geographical regions to gain a better understanding of the market and provide an accurate analysis. The regional analysis coversNorth America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

Objectives of the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-therapy-market/

Thank you for reading our report. To learn more about report details or for customization information, please contact us. Our team will ensure that the report is customized according to your requirements.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Read the rest here:
Stem Cell Therapy Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 - The Daily Chronicle

Stem Cell Manufacturing Market 2020 Global Industry Analysis, Size, Growth, Trends, Share, COVID-19 Impact Analysis, and Forecast 2027| Merck Group,…

By Embryonic Stem Cells

Data Bridge Market Research recently introducedGlobal Stem Cell Manufacturing Market Size, Industry Share, Growth, Industry Trends and Forecast To 2027study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2027. Global Stem Cell Manufacturing Market explores effective study on varied sections of Industry like opportunities, size, growth, technology, demand and trend of high leading players. It also provides market key statistics on the status of manufacturers, a valuable source of guidance, direction for companies and individuals interested in the industry. This report showcases the latest trends in the global and regional markets on all critical parameters which include technology, supplies, capacity, production, profit, price, and competition. The growth of the Stem Cell Manufacturing market was mainly driven by the increasing R&D spending across the world, however latest COVID scenario and economic slowdown have changed complete market dynamics.

Stem cell manufacturing is forecasted to grow at CAGR of 6.42% to an anticipated value of USD 18.59 billion by 2027 with factors like rising awareness towards diseases like cancer, degenerative disorders and hematopoietic disorders is driving the growth of the market in the forecast period of 2020-2027.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-manufacturing-market&AB

Stem cell manufacturing has shown an exceptional penetration in North America due to increasing research in stem cell. Increasing research and development activities in biotechnology and pharmaceutical sector is creating opportunity for the stem cell manufacturing market.

The Global Stem Cell Manufacturing Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Manufacturing Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Global Stem Cell Manufacturing Market Segematation By Product (Stem Cell Line, Instruments, Culture Media, Consumables), Application (Research Applications, Clinical Applications, Cell and Tissue Banking), End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others)

List of TOP KEY PLAYERS in Stem Cell Manufacturing Market Report are

Thermo Fisher Scientific Merck KGaA BD JCR Pharmaceuticals Co., Ltd Organogenesis Inc Osiris Vericel Corporation AbbVie Inc AM-Pharma B.V ANTEROGEN.CO.,LTD Astellas Pharma Inc Bristol-Myers Squibb Company FUJIFILM Cellular Dynamics, Inc RHEACELL GmbH & Co. KG Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Ltd ViaCyte,Inc VistaGen Therapeutics Inc GlaxoSmithKline plc ..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-manufacturing-market&AB

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell Manufacturing industry. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell Manufacturing manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The Global Stem Cell Manufacturing Market Trends, development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product, the stem cell manufacturing market is segmented into stem cell lines, instruments, culture media and consumables. Stem cell lines are further segmented into induced pluripotent stem cells, embryonic stem cells, multipotent adult progenitor stem cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells. Instrument is further segmented into bioreactors and incubators, cell sorters and other instruments.

On the basis of application, the stem cell manufacturing market is segmented into research applications, clinical applications and cell and tissue banking. Research applications are further segmented into drug discovery and development and life science research. Clinical applications are further segmented into allogenic stem cell and autologous stem cell therapy.

On the basis of end users, the stem cell manufacturing market is segmented into hospitals and surgical centers, pharmaceutical and biotechnology companies, research institutes and academic institutes, community healthcare, cell banks and tissue banks and others.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Key Insights in the report:

Historical and current market size and projection up to 2025

Market trends impacting the growth of the global taste modulators market

Analyze and forecast the taste modulators market on the basis of, application and type.

Trends of key regional and country-level markets for processes, derivative, and application Company profiling of key players which includes business operations, product and services, geographic presence, recent developments and key financial analysis

For More Information or Query or Customization Before Buying, Visit @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market&AB

Opportunities in the market

To describe and forecast the market, in terms of value, for various segments, by region North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW)

The key findings and recommendations highlight crucial progressive industry trends in the Stem Cell manufacturing Market, thereby allowing players to develop effective long term strategies

To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders Extensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across Europe.

To get a comprehensive overview of the Stem Cell manufacturing market.

With tables and figures helping analyses worldwide Global Stem Cell Manufacturing Market Forecast this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. There are 15 Chapters to display the Stem Cell Manufacturing market.

Chapter 1, About Executive Summary to describe Definition, Specifications and Classification of Stem Cell Manufacturing market, By Product Type, by application, by end users and regions.

Chapter 2, objective of the study.

Chapter 3, to display Research methodology and techniques.

Chapter 4 and 5, to show the Stem Cell Manufacturing Market Analysis, segmentation analysis, characteristics;

Chapter 6 and 7, to show Five forces (bargaining Power of buyers/suppliers), Threats to new entrants and market condition;

Chapter 8 and 9, to show analysis by regional segmentation[North America, Europe, Asia-Pacific etc ], comparison, leading countries and opportunities; Regional Marketing Type Analysis, Supply Chain Analysis

Chapter 10, to identify major decision framework accumulated through Industry experts and strategic decision makers;

Chapter 11 and 12, Stem Cell Manufacturing Market Trend Analysis, Drivers, Challenges by consumer behavior, Marketing Channels

Chapter 13 and 14, about vendor landscape (classification and Market Ranking)

Chapter 15, deals with Stem Cell Manufacturing Market sales channel, distributors, Research Findings and Conclusion, appendix and data source.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Our Upcoming Event: Rare Disease and Orphan Drugs |Digital Conference

Go here to see the original:
Stem Cell Manufacturing Market 2020 Global Industry Analysis, Size, Growth, Trends, Share, COVID-19 Impact Analysis, and Forecast 2027| Merck Group,...

Cancer Therapy Market 2020 Size and Share by Growth Opportunities, Segmentation, Regional Insights, Key Trends, Demand and Outlook by 2024 – Verdant…

By Gene Therapy Clinics

Several big pharmaceutical companies, such as Pfizer and Eli lily, have also started these programs to help uninsured patients who are suffering from chronic diseases. Thus, a large number of uninsured patients, suffering from cancer, can also undergo cancer therapies, which is likely to augment the growth of the market.

Scope of the Report:

As per the , cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. These therapies include surgery, radiation therapy, chemotherapy, immunotherapy, etc.

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999546

Key Market Trends:

The Target Therapy Segment is Expected to show the Fastest Growth in the Forecast Period

The target therapy segment is expected to show the highest CAGR of 9.68% during the forecast period. The target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells.

The breast cancer segment is belived to account for the largest market size over the forecast period. This is majorly attrobuted to the higher and continuously increaisng prevalence of breast cancer acoss the world. As per estimates provided by the Breast Cancer Organization in 2018, it is estimated that over 2,66,120 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer.

North America Currently Dominates the Cancer Therapy Market and is Expected to Continue in the Forecast Period

North America currently dominates the market for cancer therapy and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of cancer therapy. The United States holds majority of the market in the North American region, due to the rising prevalence of cancer in the country. According to the National Cancer Institute (NCI), in 2016, 1.6 million people suffered from cancer, and around 0.5 million people died from cancer. This figure indicates that the prevalence of cancer is rapidly increasing in the United States.

Cancer Therapy Market Report contents include:

Purchase this Report (Price 4500 USD for single user license) https://www.industryresearch.co/purchase/13999546

Detailed TOC of Cancer Therapy Market Report 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Patient Assistance Programs (PAPs) 4.2.2 Growing Government Initiatives for Cancer Awareness 4.2.3 Rising Prevalence of Cancer Worldwide 4.2.4 Strong R&D Initiatives from Key Players 4.3 Market Restraints 4.3.1 Fluctuation in Reimbursement Policies 4.3.2 High Cost of Cancer Therapies 4.4 Porters Five Force Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Treatment Type 5.1.1 Chemotherapy 5.1.2 Targeted Therapy 5.1.3 Immunotherapy 5.1.4 Hormonal Therapy 5.1.5 Other Treatment Types 5.2 By Cancer Type 5.2.1 Blood Cancer 5.2.2 Breast Cancer 5.2.3 Prostate Cancer 5.2.4 Gastrointestinal Cancer 5.2.5 Gynecologic Cancer 5.2.6 Respiratory/Lung Cancer 5.2.7 Other Cancer Types 5.3 By End User 5.3.1 Hospitals 5.3.2 Spcialty Clinics 5.3.3 Cancer and Radiation Therapy Centers 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 South Korea 5.4.3.5 Australia 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East & Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East & Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Amgen Inc. 6.1.2 AstraZeneca PLC 6.1.3 Bayer AG 6.1.4 Johnson and Johnson 6.1.5 Merck & Co. Inc. 6.1.6 F. Hoffmann-La Roche AG 6.1.7 Eli Lilly and Company 6.1.8 Novartis AG 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

About Industry Research:

Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Ophthalmic Ultrasound Systems Market Size by Impressive Growth Rate 2020 Business Size, Global Share, Industry Overview by Future Plans, Top Key Players Forecast to 2026 | Report by Industry Research.co

Bouillon Cubes Market Size by Impressive Growth Rate 2020 Business Size, Global Share, Industry Overview by Future Plans, Top Key Players Forecast to 2026 | Report by Industry Research.co

Ultra-Thin Glass Market Growth Analysis by Future Trends 2020 Industry Size by Top Players, Development Plans, Business Share, Revenue and Opportunities till 2026

Foldable Display Market Size by Future Scope 2020 | Global Industry Revenue, Share, Future Demand Status, Growth Segmentations Analysis by Regions Forecast to 2026

Intravenous (IV) Solution Market Growth Analysis by Future Trends 2020 Industry Size by Top Players, Development Plans, Business Share, Revenue and Opportunities till 2026

Brine Concentration Market Size Analysis 2020 Global Industry Scope, Key Players, Top Regions, Current Industry Trend with Growth Rate, CAGR Status Forecast to 2026 | Report by Industry Research.co

Artificial Joint Replacement Market Size Report 2020 Market Dynamics and Developments, Industry Research Report by Top Manufactures, Types, Applications Forecast to 2026

Follow this link:
Cancer Therapy Market 2020 Size and Share by Growth Opportunities, Segmentation, Regional Insights, Key Trends, Demand and Outlook by 2024 - Verdant...

→←